A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs LY 3002813 (Primary) ; LY 3002813 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly
- 20 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.
- 20 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 18 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.